Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension.

[1]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[2]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[3]  S. Archer,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension Comparison With Inhaled Nitric Oxide , 2002 .

[4]  W. Seeger,et al.  Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.

[5]  R. Barst,et al.  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[6]  L. Rubin,et al.  Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. , 2002, American journal of respiratory cell and molecular biology.

[7]  R. Ewert,et al.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.

[8]  R. Lookstein,et al.  Flolan infusion interruption: a lethal complication during venous access. , 2001, Journal of vascular and interventional radiology : JVIR.

[9]  F. Sakamaki,et al.  Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy , 2000, Circulation.

[10]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[11]  B. Groves,et al.  Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. , 1999, Circulation.

[12]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[13]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[14]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[15]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.